FDA Panel Considers Loosening Regulations on Unapproved Peptides
An FDA advisory panel is reviewing whether compounding pharmacies can fill prescriptions for certain unapproved peptides, amid growing interest in these therapies. Peptides, which are short strings of amino acids, are used in various approved medications, but some unapproved peptides are marketed for benefits like anti-aging and muscle growth without scientific backing. The panel is considering adding seven peptides to a list of substances that can be safely compounded, including BPC-157, which is popular among wellness influencers. The decision follows a vote to broaden access to BPC-157, despite concerns about the lack of extensive human testing. 
